Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 11;113(27-28):470-6.
doi: 10.3238/arztebl.2016.0470.

The Diagnosis and Treatment of Multiple Myeloma

Christian Gerecke  1 , Stephan Fuhrmann, Susanne Strifler, Martin Schmidt-Hieber, Hermann Einsele, Stefan Knop
Affiliations
Review

The Diagnosis and Treatment of Multiple Myeloma

Christian Gerecke et al. Dtsch Arztebl Int. .

Abstract

Background: Multiple myeloma is a malignant disease of plasma cells with a worldwide incidence of 6-7 cases per 100 000 persons per year. It is among the 20 most common types of cancer in Germany.

Methods: This review is based on pertinent publications up to December 2015 that were retrieved by a selective search of PubMed employing the terms "multiple myeloma" AND "therapy" OR "diagnostic." Systematic reviews, meta-analyses, randomized controlled trials, and treatment recommendations from Germany and abroad were considered.

Results: The diagnostic evaluation of multiple myeloma comprises thorough history-taking and physical examination, various laboratory tests including analysis of a 24-hour urine sample, a bone-marrow biopsy, and skeletal radiography. Systemic treatment should be administered only when organ damage has been diagnosed. The type of treatment to be given is chosen individually on the basis of the patient's age, comorbidities, and risk profile. High-dose therapy with autologous stem-cell transplantation remains the treatment of choice for patients under age 70 who are otherwise in good health. For patients who are not candidates for high-dose therapy or who have had a recurrence of multiple myeloma after prior high-dose therapy, there are a number of further conventional treatment options. Patients need not only systemic antineoplastic treatment, but also supportive treatment for the prevention of treatment-induced toxicity and myeloma-associated organ damage.

Conclusion: Recent therapeutic advances have made the treatment of multiple myeloma both more complex and more costly. In particular, the median survival of patients with multiple myeloma has been markedly prolonged through the use of targeted drugs such as proteasome inhibitors and immune modulators.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk-adjusted treatment algorithm for newly diagnosed patients with multiple myeloma requiring treatment MEL, melphalan; MPT, melphalan, prednisone and thalidomide; PAD, Velcade (bortezomib), adriamycin, dexamethasone; Rd, lenalidomide, dexamethasone; VCD, Velcade, cyclophosphamide, dexamethasone; VMP, Velcade, melphalan, prednisolone; VTD, Velcade, thalidomide, dexamethasone; ASCT, autologous stem cell transplantation; CR, complete remission; HDT high-dose treatment
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, et al. Lyon, France: IARC Press;; 2008. WHO classification of tumours of haematopoietic and lymphoid tissues.
    1. Robert Koch-Institut: Krebs in Deutschland 2009/2010. www.krebsdaten.de/Krebs/DE/Home/homepage_node.html. 9th edition. 2013. (last accessed on 22 September 2015)
    1. Landgren O, Kyle RA, Pfeifer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113:5412–5417. - PMC - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–1369. - PubMed
    1. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069–3075. - PMC - PubMed

MeSH terms

Substances